SE459970B - Ergolin-8-yl-sulfamid, saett att framstaella denna och en farmaceutisk komposition - Google Patents

Ergolin-8-yl-sulfamid, saett att framstaella denna och en farmaceutisk komposition

Info

Publication number: SE459970B
Authority: SE; Sweden
Prior art keywords: formula; compounds; acid addition; ethyl; pharmaceutical composition
Prior art date: 1983-02-16

Application number

SE8400782A

Other languages

English (en)

Swedish (sv)

Other versions

SE8400782D0 (sv

SE8400782L (sv

Inventor

P Pfaeffli

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-02-16

Filing date

1984-02-14

Publication date

1989-08-28

1983-02-16 Priority claimed from CH862/83A external-priority patent/CH652719A5/de

1983-02-16 Priority claimed from CH86383A external-priority patent/CH652720A5/de

1984-02-14 Application filed by Sandoz Ag filed Critical Sandoz Ag

1984-02-14 Publication of SE8400782D0 publication Critical patent/SE8400782D0/xx

1984-08-17 Publication of SE8400782L publication Critical patent/SE8400782L/xx

1989-08-28 Publication of SE459970B publication Critical patent/SE459970B/sv

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 3
150000001875 compounds Chemical class 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
238000000034 method Methods 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
239000012458 free base Substances 0.000 claims 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
239000002585 base Substances 0.000 claims 2
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
102000003946 Prolactin Human genes 0.000 description 4
108010057464 Prolactin Proteins 0.000 description 4
229940097325 prolactin Drugs 0.000 description 4
230000028327 secretion Effects 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000027089 Parkinsonian disease Diseases 0.000 description 2
206010034010 Parkinsonism Diseases 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
230000003291 dopaminomimetic effect Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 2
MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
206010015995 Eyelid ptosis Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000095 emetic effect Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
201000003004 ptosis Diseases 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
229960005333 tetrabenazine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
- C07D457/12—Nitrogen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE8400782A 1983-02-16 1984-02-14 Ergolin-8-yl-sulfamid, saett att framstaella denna och en farmaceutisk komposition SE459970B (sv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH862/83A CH652719A5 (en)	1983-02-16	1983-02-16	Ergoline derivatives, their preparation and use
CH86383A CH652720A5 (en)	1983-02-16	1983-02-16	Ergoline derivatives, their preparation and use

Publications (3)

Publication Number	Publication Date
SE8400782D0 SE8400782D0 (sv)	1984-02-14
SE8400782L SE8400782L (sv)	1984-08-17
SE459970B true SE459970B (sv)	1989-08-28

Family

ID=25685928

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8400782A SE459970B (sv)	1983-02-16	1984-02-14	Ergolin-8-yl-sulfamid, saett att framstaella denna och en farmaceutisk komposition

Country Status (22)

Country	Link
US (1)	US4791116A (fi)
AT (1)	AT386410B (fi)
AU (1)	AU572822B2 (fi)
CA (1)	CA1208630A (fi)
DE (1)	DE3404400A1 (fi)
DK (1)	DK67284A (fi)
ES (1)	ES8505252A1 (fi)
FI (1)	FI80034C (fi)
FR (1)	FR2540874B1 (fi)
GB (1)	GB2135307B (fi)
GR (1)	GR81770B (fi)
HU (1)	HU196399B (fi)
IE (1)	IE56871B1 (fi)
IL (1)	IL70954A (fi)
IT (1)	IT1199062B (fi)
MY (1)	MY8700270A (fi)
NL (1)	NL8400333A (fi)
NZ (1)	NZ207145A (fi)
PH (1)	PH24707A (fi)
PL (1)	PL246230A1 (fi)
PT (1)	PT78101B (fi)
SE (1)	SE459970B (fi)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3915950A1 (de) *	1989-05-12	1990-11-15	Schering Ag	8(alpha)-acylamino-ergoline, ihre herstellung und verwendung als arzneimittel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4348392A (en) *	1974-07-19	1982-09-07	Sandoz Ltd.	8α-Substituted ergoline-I derivatives
GB1573621A (en) *	1976-01-02	1980-08-28	Sandoz Ltd	Acylated 6-methyl-8a-amino-ergoline i compounds
DE2656344A1 (de) *	1975-12-23	1977-07-07	Sandoz Ag	Ergolinderivate, ihre verwendung und herstellung
CH622518A5 (en) *	1976-12-14	1981-04-15	Sandoz Ag	Process for the preparation of novel ergoline compounds
CH654838A5 (fr) *	1980-07-25	1986-03-14	Sandoz Ag	Ergolinderivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammensetzungen.
DE3151912A1 (de) *	1981-12-23	1983-06-30	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue ergolin-aminoderivate, verfahren zu ihrer herstellung und deren verwendung als arzneimittel
PH21123A (en) *	1983-04-28	1987-07-27	Erba Farmitalia	Ergoline derivatives

1984
- 1984-02-03 NL NL8400333A patent/NL8400333A/nl not_active Application Discontinuation
- 1984-02-03 HU HU84463A patent/HU196399B/hu not_active IP Right Cessation
- 1984-02-08 DE DE19843404400 patent/DE3404400A1/de not_active Withdrawn
- 1984-02-09 FR FR8402128A patent/FR2540874B1/fr not_active Expired
- 1984-02-13 GB GB08403723A patent/GB2135307B/en not_active Expired
- 1984-02-13 PL PL24623084A patent/PL246230A1/xx unknown
- 1984-02-14 IL IL70954A patent/IL70954A/xx unknown
- 1984-02-14 IT IT47681/84A patent/IT1199062B/it active
- 1984-02-14 PT PT78101A patent/PT78101B/pt not_active IP Right Cessation
- 1984-02-14 PH PH30239A patent/PH24707A/en unknown
- 1984-02-14 SE SE8400782A patent/SE459970B/sv not_active IP Right Cessation
- 1984-02-14 NZ NZ207145A patent/NZ207145A/en unknown
- 1984-02-14 DK DK67284A patent/DK67284A/da not_active Application Discontinuation
- 1984-02-14 GR GR73799A patent/GR81770B/el unknown
- 1984-02-14 FI FI840587A patent/FI80034C/fi not_active IP Right Cessation
- 1984-02-14 CA CA000447409A patent/CA1208630A/en not_active Expired
- 1984-02-15 IE IE353/84A patent/IE56871B1/xx unknown
- 1984-02-15 AU AU24625/84A patent/AU572822B2/en not_active Ceased
- 1984-02-15 AT AT0047984A patent/AT386410B/de not_active IP Right Cessation
- 1984-02-15 ES ES529759A patent/ES8505252A1/es not_active Expired
1986
- 1986-12-01 US US06/936,204 patent/US4791116A/en not_active Expired - Fee Related
1987
- 1987-12-30 MY MY270/87A patent/MY8700270A/xx unknown

Also Published As

Publication number	Publication date
US4791116A (en)	1988-12-13
GB8403723D0 (en)	1984-03-14
IE56871B1 (en)	1992-01-15
IE840353L (en)	1984-08-16
IL70954A0 (en)	1984-05-31
GR81770B (fi)	1984-12-12
ES529759A0 (es)	1985-05-16
FR2540874B1 (fr)	1986-08-29
MY8700270A (en)	1987-12-31
DK67284D0 (da)	1984-02-14
GB2135307A (en)	1984-08-30
HU196399B (en)	1988-11-28
CA1208630A (en)	1986-07-29
FI80034B (fi)	1989-12-29
DE3404400A1 (de)	1984-08-16
HUT34474A (en)	1985-03-28
ES8505252A1 (es)	1985-05-16
FI80034C (fi)	1990-04-10
PT78101A (en)	1984-03-01
FI840587A0 (fi)	1984-02-14
SE8400782D0 (sv)	1984-02-14
NL8400333A (nl)	1984-09-17
PL246230A1 (en)	1985-02-13
GB2135307B (en)	1986-07-30
DK67284A (da)	1984-08-17
AT386410B (de)	1988-08-25
SE8400782L (sv)	1984-08-17
FR2540874A1 (fr)	1984-08-17
AU572822B2 (en)	1988-05-19
ATA47984A (de)	1988-01-15
PT78101B (en)	1986-07-15
FI840587A (fi)	1984-08-17
IT8447681A0 (it)	1984-02-14
AU2462584A (en)	1984-08-23
NZ207145A (en)	1987-06-30
PH24707A (en)	1990-10-01
IL70954A (en)	1987-10-20
IT1199062B (it)	1988-12-30

Publication	Publication Date	Title
US3818035A (en)	1974-06-18	2{8 (2-ALKYLBENZO{8 b{9 {11 FURAN-3 yl)METHYL{9 -{66 {11 IMIDAZOLINE
GB1016514A (en)	1966-01-12	2-aryl-amino-1,3-diazacyclopentenes
US4512998A (en)	1985-04-23	Anthelmintic benzimidazole carbamates
US3140231A (en)	1964-07-07	T-octylguanidines as antihypertensive agents
US6753333B2 (en)	2004-06-22	Chiral fluoroquinolone arginine salt forms
US4147780A (en)	1979-04-03	α-Amino-phosphonous acids for inhibiting bacteria and yeast
CS229940B2 (en)	1984-07-16	Production method substiuted pyridazine derivatives
KR880009987A (ko)	1988-10-06	위치 7에서 치환된 19-노르스테로이드, 이들의 제조방법, 약으로서의 사용방법 및 이들을 함유하는 약리학적 조성물
HU184271B (en)	1984-07-30	Process for preparing imidazolidine derivatives
KR900014396A (ko)	1990-10-23	티에노-트리아졸로-디아제핀 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
US2742462A (en)	1956-04-17	New n-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidones
FI62074B (fi)	1982-07-30	Foerfarande foer framstaellning av nya farmakologiskt aktiva 5-fenyl-oxazolidinon-2-foereningar
IE47122B1 (en)	1983-12-28	3-indolyl-tertiary butylaminopropanols
SE459970B (sv)	1989-08-28	Ergolin-8-yl-sulfamid, saett att framstaella denna och en farmaceutisk komposition
CZ70594A3 (en)	1994-12-15	Thiadiazinones
SE445552B (sv)	1986-06-30	N-substituerade 2-cyanaziridiner forfarande for framstellning derav samt komposition derav
GB2059963A (en)	1981-04-29	2-Amino-3-benzoyl- phenylacetamides and cyclic homologues
ES2203955T3 (es)	2004-04-16	7-acilamino-3-(metilhidrazono)metil-cefalosporinas sustituidas antibacterianas y productos intermedios.
US2847416A (en)	1958-08-12	Nu-[1-(5-nitro-2-furyl) ethylidene]-3-amino-2-oxazolidone
CA1070616A (en)	1980-01-29	Anti-tumor composition
CA1037058A (en)	1978-08-22	4-acylaminophenylacetamidines and a method for their preparation
JPH0327367A (ja)	1991-02-05	新規な２―アミノ―５―アリールオキシメチルオキサゾリンとその塩
US3303207A (en)	1967-02-07	d-threo-chloramphenico phenyldioxaboran derivative
US3911126A (en)	1975-10-07	Compositions comprising thiocarbamic acid derivatives and method of using same
EP0022737B1 (fr)	1982-06-09	Imines dérivées de l'amino-5 benzodioxole-1,3 utiles comme médicaments et leur préparation

Legal Events

Date	Code	Title	Description
1995-01-31	NUG	Patent has lapsed	Ref document number: 8400782-2 Effective date: 19910911 Format of ref document f/p: F

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8400782-2

Effective date: 19910911

Format of ref document f/p: F